Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (371-380 of 738) with videos related to

Pageof 74
Sort By:
Gynecologic Oncology|December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group studyNefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
Gynecologic Oncology|February 27, 2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancerRebecca C Arend, Bradley J Monk, Thomas J Herzog, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2025
ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancerMario M Leitao, Kristin L Bixel, Dana Meredith Chase, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyD Lorusso, N Colombo, C Dubot, et al.
The New England Journal of Medicine|March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K Chan, Mark F Brady, Richard T Penson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Archives of Gynecology and Obstetrics|April 23, 2019
A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancerG F Vercellino, E Erdemoglu, P Lichtenberg, et al.
JAMA Oncology|February 6, 2016
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian CarcinomaElizabeth M Swisher, Maria I Harrell, Barbara M Norquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Integrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyBradley J Monk, Andrea Facciabene, William E Brady, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behaviorMai-Anh T Vu, Eleanor H Brown, Michelle J Wen, et al.
Pageof 74

Showing results (371-380 of 738) with videos related to

Sort By:
Pageof 74
Gynecologic Oncology|December 3, 2021
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group studyNefertiti C duPont, Danielle Enserro, Mark F Brady, et al.
Gynecologic Oncology|February 27, 2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancerRebecca C Arend, Bradley J Monk, Thomas J Herzog, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2025
ROCC/GOG-3043: a randomized controlled trial of robotic versus open surgery for early-stage cervical cancerMario M Leitao, Kristin L Bixel, Dana Meredith Chase, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2024
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 studyD Lorusso, N Colombo, C Dubot, et al.
The New England Journal of Medicine|March 3, 2016
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerJohn K Chan, Mark F Brady, Richard T Penson, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 2023
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerAntonio González-Martín, Bhavana Pothuri, Ignace Vergote, et al.
Archives of Gynecology and Obstetrics|April 23, 2019
A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancerG F Vercellino, E Erdemoglu, P Lichtenberg, et al.
JAMA Oncology|February 6, 2016
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian CarcinomaElizabeth M Swisher, Maria I Harrell, Barbara M Norquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Integrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyBradley J Monk, Andrea Facciabene, William E Brady, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2023
Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behaviorMai-Anh T Vu, Eleanor H Brown, Michelle J Wen, et al.
Pageof 74